A novel dual DYRK1A/B inhibitor for the treatment of type 1 diabetes

Related Experiment Video

Updated: Jan 13, 2026

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
07:30

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

9.7K

Šarūnas Tumas1, Jonas Mingaila2, Vytautas Baranauskas1,3

  • 1Cureline Baltic UAB, Vilnius, Lithuania.

Frontiers in Pharmacology
|October 29, 2025
PubMed
Abstract

Insights

A novel DYRK1 inhibitor, FX8474, showed modest improvements in glucose regulation and altered immune cell populations in a type 1 diabetes mouse model. Further research is needed to explore its therapeutic potential for beta cell regeneration.

Area of Science:

  • Endocrinology
  • Immunology
  • Pharmacology

Background:

  • Type 1 diabetes (T1D) involves autoimmune destruction of pancreatic beta cells, leading to insulin deficiency.
  • Current T1D treatments rely on insulin replacement, highlighting the need for beta cell regeneration strategies.
  • Dual-specificity tyrosine-phosphorylation-regulated kinases 1A (DYRK1A) and 1B (DYRK1B) are implicated in beta cell proliferation.

Purpose of the Study:

  • To evaluate the efficacy of FX8474, a novel DYRK1 inhibitor, in a mouse model of type 1 diabetes.
  • To assess the impact of FX8474 on glucose regulation and immune cell profiles.

Main Methods:

  • A streptozotocin (STZ)-induced diabetic mouse model was used.
  • Mice received oral administration of FX8474 for seven days.
  • Pharmacokinetics, glucose levels, glucose tolerance, and immune cell populations were analyzed.

Main Results:

  • FX8474 demonstrated oral bioavailability and improved fasted glucose levels and glucose tolerance after seven days of treatment.
  • Immunophenotyping revealed an increase in CD4+ memory T cells and a decrease in CD4+ effector cells.
  • FX8474 treatment restored CD8+ T cell phenotypes to levels seen in healthy mice.

Conclusions:

  • FX8474 exhibited a modest effect on glucose regulation and immune cell composition in the STZ-induced diabetic mouse model.
  • The findings suggest that FX8474 warrants further investigation for its potential therapeutic applications in type 1 diabetes.
Keywords:
DYRK1DYRK1A kinaseDYRK1B kinaseGTTstreptozotocintype 1 diabetes

More Related Videos

Author Spotlight: Understanding Retinal Vessel Resilience and Disease Progression04:36

Author Spotlight: Understanding Retinal Vessel Resilience and Disease Progression

Published on: January 12, 2024

1.6K
Isolated Pancreatic Islet Treatment and Apoptosis Measurement09:36

Isolated Pancreatic Islet Treatment and Apoptosis Measurement

Published on: May 2, 2025

821

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
836
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
575
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
4.8K
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
593
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
858
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
581